Antiviral Potential of Azelastine against Major Respiratory Viruses
Viruses · 2023
DOI: 10.3390/v15122300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Katrin Fischhuber und 10 weiteren Autor:innen. Beteiligte Einrichtung: CEBINA GmbH, 1030 Vienna, Austria. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent increase in respiratory viral infections highlight the need for broad-spectrum antivirals to enable a quick and efficient reaction to current and emerging viral outbreaks. We previously demonstrated that the antihistamine azelastine hydrochloride (azelastine-HCl) exhibited in vitro antiviral activity against SARS-CoV-2. Furthermore, in a phase 2 clinical study, a commercial azelastine-containing nasal spray significantly reduced the viral load in SARS-CoV-2-infected individuals. Here, we evaluate the efficacy of azelastine-HCl against additional human coronaviruses, including the SARS-CoV-2 omicron variant and a seasonal human coronavirus, 229E, through in vitro infection assays, with azelastine showing a comparable potency against both. Furthermore, we determined that azelastine-HCl also inhibits the replication of Respiratory syncytial virus A (RSV A) in both prophylactic and therapeutic settings. In a human 3D nasal tissue model (MucilAirTM-Pool, Epithelix), azelastine-HCl protected tissue integrity and function from the effects of infection with influenza A H1N1 and resulted in a reduced viral load soon after infection. Our results suggest that azelastine-HCl has a broad antiviral effect and can be considered a safe option against the most common respiratory viruses to prevent or treat such infections locally in the form of a nasal spray that is commonly available globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CEBINA GmbH, 1030 Vienna, Austria.
- Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Zoltán Bánki, Janine Kimpel, Annika Rössler
Zitieren
APA
Fischhuber, K., Bánki, Z., Kimpel, J., Kragl, N., Rössler, A., Bolze, A., Muellauer, B., Angerer, J., Nagy, G., Nagy, E., & Szijarto, V. (2023). Antiviral Potential of Azelastine against Major Respiratory Viruses. Viruses. https://doi.org/10.3390/v15122300
Vancouver
Fischhuber K, Bánki Z, Kimpel J, Kragl N, Rössler A, Bolze A, et al. Antiviral Potential of Azelastine against Major Respiratory Viruses. Viruses. 2023. doi:10.3390/v15122300
BibTeX
@article{Fischhuber2023,
author = {Fischhuber, Katrin and Bánki, Zoltán and Kimpel, Janine and Kragl, Natalie and Rössler, Annika and Bolze, Annika and Muellauer, Brigitte and Angerer, Joachim and Nagy, Gábor and Nagy, Eszter and Szijarto, Valeria},
title = {Antiviral Potential of Azelastine against Major Respiratory Viruses},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15122300}
}
EUVIMED